10x Genomics, Inc. (TXG) AI Stock Analysis

10x Genomics, Inc. is a life science technology company that develops and markets instruments, consumables, and software for comprehensive biological system analysis across North America, Europe, Asia Pacific, and other global markets. Its product portfolio includes chromium and chromium connect instruments, microfluidic chips, slides, and reagents supporting proprietary single cell solutions. These systems enable applications like single cell gene expression analysis, single cell immune profiling, and chromatin accessibility assessments through ATAC and multiome platforms. The company also offers the visium spatial gene expression platform to map gene expression within tissue samples.

From FY2021 to FY2025, revenue expanded from $490.5M to $642.8M, marking a 5-year revenue CAGR of 16.6%. Annual revenue growth was 64.1% in FY2021, 5.3% in FY2022, 19.8% in FY2023, -1.3% in FY2024, and 5.2% in FY2025. Gross margin contracted from 84.9% in FY2021 to 69.1% in FY2025. The company posted net losses across each fiscal year, improving from a net loss of -$255.1M in FY2023 to -$43.5M in FY2025, with EPS rising to $0.23. For the trailing twelve months ended June 30, 2026, revenue stood at $616.9M, with quarterly revenue growth falling 12.7% year-over-year and an operating margin of -15.2%.

As of June 30, 2026, 10x Genomics reported $552.0M in cash and short-term investments against total debt of $78.8M, resulting in net cash of $473.2M. Total assets reached $1.03B compared to shareholders' equity of $825.5M, reflecting a debt-to-equity ratio of 0.10 and a current ratio of 5.69. For FY2025, the company generated $136.1M in operating cash flow and $130.1M in free cash flow after capital expenditures of $5.9M. Over five years, the share count increased 16.2%.

At a closing price of $69.86 on October 16, 2026, 10x Genomics had a market cap of $9.10B and an enterprise value of $9.38B. The company trades at a price-to-sales multiple of 14.8x and an EV-to-revenue multiple of 15.2x, compared to the median price-to-sales multiple of 4.1x for its US-listed Healthcare peers. Its EV-to-EBITDA stands at 148.5x versus the peer median of 12.0x. Over the past year, the stock returned 464.3%, significantly outpacing the 16.8% return of the S&P 500, though its 5-year return of -54.1% lagged the index's 83.0% gain.

Wall Street coverage consists of 6 Strong Buy, 1 Buy, and 12 Hold recommendations, with zero Sell ratings. The mean price target of $77.00 implies an upside of 10.2% over the last close of $69.86. For the fiscal year ending December 31, 2026, analysts estimate revenue of $620.7M and EPS of $0.04. For the next fiscal year, consensus projects revenue to grow 10.1% to $683.6M and EPS of $0.08. The company has beat EPS estimates in each of the last 4 quarters, with next earnings scheduled for November 5, 2026.

This page is an AI-written research summary of 10x Genomics, Inc. (TXG). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TXG income statement, TXG balance sheet, TXG key metrics, TXG analyst forecast, TXG chart. See the TXG stock overview for the latest quote and news.